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Abstract
Background: Preeclampsia is thought to originate during placentation, with incomplete remodelling and perfusion
of the spiral arteries leading to reduced placental vascular capacity. Nitric oxide (NO) and carbon monoxide (CO)
are powerful vasodilators that play a role in the placental vascular system. Although family clustering of
preeclampsia has been observed, the existing genetic literature is limited by a failure to consider both mother and
child.
Methods: We conducted a nested case–control study within the Norwegian Mother and Child Birth Cohort of 1545
case-pairs and 995 control-pairs from 2540 validated dyads (2011 complete pairs, 529 missing mother or child
genotype). We selected 1518 single-nucleotide polymorphisms (SNPs) with minor allele frequency >5% in NO and
CO signalling pathways. We used log-linear Poisson regression models and likelihood ratio tests to assess
maternal and child effects.
Results: One SNP met criteria for a false discovery rate Q-value <0.05. The child variant, rs12547243 in adenylate
cyclase 8 (ADCY8), was associated with an increased risk (relative risk [RR] 1.42, 95% confidence interval [CI] 1.20,
1.69 for AG vs. GG, RR 2.14, 95% CI 1.47, 3.11 for AA vs. GG, Q = 0.03). The maternal variant, rs30593 in PDE1C
was associated with a decreased risk for the subtype of preeclampsia accompanied by early delivery (RR 0.45, 95%
CI 0.27, 0.75 for TC vs. CC; Q = 0.02). None of the associations were replicated after correction for multiple testing.
Conclusions: This study uses a novel approach to disentangle maternal and child genotypic effects of NO and CO
signalling genes on preeclampsia.
Keywords: preeclampsia, genetic epidemiology, family based design, mother–child dyad, case–control, Norwegian Mother
and Child Cohort Study, MoBa.
definitive treatment is delivery, and it is associated
with serious maternal and foetal morbidity and
mortality.1
Although incompletely understood, preeclampsia is
hypothesized to originate during placentation.1 Thus,
both maternal and foetal components may contribute
to the condition. During normal placentation, the foe-
tal cytotrophoblast invades the maternal decidua,
Preeclampsia is a serious pregnancy complication, 
affecting approximately 2%–7% of pregnant women, 
characterized by new-onset gestational hypertension 
and proteinuria after 20 weeks’ gestation.1 The only
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penetrating maternal spiral arteries and increasing
vascular dilation. It is hypothesized that incomplete
remodelling and perfusion of the spiral arteries leads
to placental ischaemia and hypoxia,2,3 increasing
maternal endothelial dysfunction and the subsequent
clinical symptoms of preeclampsia.3
Nitric oxide (NO) and carbon monoxide (CO) are
powerful vasodilators4,5 that may improve vascular
capacity during spiral artery remodelling, thereby
promoting healthy placental development and reduc-
ing risk of preeclampsia. NO and CO are produced
endogenously as well as inhaled from exogenous
sources.6,7 Measured NO production and serum
metabolites of NO are lower among women with
preeclampsia than during normal pregnancy7,8 and
women with preeclampsia have decreased amounts
of CO concentrations in their exhaled breath com-
pared to those with healthy pregnancies.9,10 NO and
CO are important in the placental vascular system5,11
and it has been suggested that NO and CO are
required for proper trophoblast differentiation and
invasion.5,11 CO is directly produced by foetal tro-
phoblast cells,5 and chorionic and umbilical endothe-
lial cells release NO.11 Because NO and CO are
associated with smooth muscle relaxation and blood
pressure regulation, they have been posited as poten-
tial explanations for the well-known inverse relation-
ship of maternal smoking with preeclampsia.3,5,7
Numerous studies have found a familial predispo-
sition for preeclampsia12 and heritability is high (ap-
proximately 50%),13 however, few consistent genetic
associations have emerged. Prior genetic studies of
preeclampsia have almost exclusively focused on
maternal DNA, which ignores the potential contribu-
tions of child genetics in disease aetiology. Isolated
variants in CO or NO-related genes (NOS3, NOS2,
HMOX1, HIF1A) have been examined in relation to
preeclampsia, or cardiovascular disease (CAV1,
ESR1, GUCY1A3, GUCY1B3, PRKCA), but these
studies have generally been small and results have
been mixed.8,14,15 A meta-analysis of the most
widely investigated SNP in NOS3 (rs1799983)
showed a slightly increased risk of preeclampsia
(OR 1.19, 95% CI 1.00, 1.42).14 In addition, in knock-
out mice and human placental expression studies,
NOS3 expression is lower in preeclamptic placen-
tas11 and HMOX1 deficiency is associated with
insufficient spiral artery remodelling.16
The objective of this study was to determine if
maternal or child single-nucleotide polymorphisms
(SNPs) in NO and CO signalling pathways were asso-
ciated with preeclampsia using a mother–child dyad
design, nested within the Norwegian Mother and
Child cohort (MoBa). We examined SNPs within three
canonical pathways important for both CO and NO
activity. Exploring both maternal and child genotype
and identifying variants that may play a role in both
endogenous and exogenous NO and CO may help




This study is a nested case–control study within the
Norwegian Mother and Child Cohort Study (MoBa),
conducted by the Norwegian Institute of Public
Health (MoBa data Version 8).17 MoBa is a large
prospective birth cohort of pregnant women and their
offspring, recruited throughout Norway from 1999 to
2008 (N = 112 908 pregnancies). All pregnant women
living in Norway who gave birth at a hospital or
maternity unit with more than 100 births annually
and who could speak Norwegian were eligible; MoBa
investigators applied no other exclusion criteria. Preg-
nant women were recruited by mail prior to their rou-
tine ultrasound appointment at 17 to 20 weeks’ of
gestation. Of all women invited to participate, 41%
enrolled in the study.17 Participants completed two
prenatal questionnaires about their health and envi-
ronment.17 Maternal blood was collected at the first
ultrasound appointment and cord blood was collected
at birth.
Outcome assessment
Birth outcome information was obtained from the
Medical Birth Registry of Norway.18 Preeclampsia
case/control status was verified using antenatal
records and hospital discharge codes, as described by
Klungsøyr and colleagues19 and in the Supplementary
Methods. Preeclampsia was defined using American
College of Obstetrics and Gynecologists (ACOG) crite-
ria.20 All observations registered as preeclampsia
cases (n = 4081) and a random sample (n = 2000) of
pregnancies registered as being unaffected by
preeclampsia were selected from MoBa to be verified
by antenatal records. Of the 3500 registered
preeclampsia cases and 1840 registered to be
unaffected by preeclampsia for which records were
received, 2936 pregnancies registered with preeclamp-
sia cases in the MBRN were verified to have been
affected by preeclampsia, and 1745 pregnancies with-
out preeclampsia registered in the MBRN were found
to be negative for preeclampsia. For this analysis, we
included from among these validated records, women
with a singleton pregnancy who conceived sponta-
neously, were verified cases or controls, returned both
early and late pregnancy questionnaires, had blood
stored in the MoBa biobank, and had no history of
chronic hypertension. After exclusion criteria, there
were 1564 cases (of which 1118 had both mother and
child DNA, and 446 had only maternal DNA) and 999
controls (of which 968 had mother and child DNA,
and 31 had only maternal DNA) that were genotyped,
for total of 4649 samples across all cases and controls,
mothers and children (Figure S1). Criteria for
preeclampsia subtypes are presented in Table 1, and
Supplementary Methods. The same set of control sam-
ples was used for each subtype analysis.
Gene and single-nucleotide polymorphisms selection
For this study, the three established Ingenuity (www.
ingenuity.com, QIAGEN, Redwood City, CA, USA)
canonical pathways involved in CO and NO sig-
nalling and synthesis were selected, which included:
(i) endothelial nitric oxide synthase (eNOS) signalling
pathway, which accomplishes the synthesis of NO
from L-arginine, (ii) haeme degradation, which
accomplishes the breakdown of haemoglobin into
CO and bilirubin, and (iii) hypoxia-inducible factor
1-alpha (HIF1A), which regulates oxygen homeostasis
and response to hypoxia. Sixty-six genes (Table S1) in
these pathways were selected for analysis, using a
10 kb upstream and downstream margin around the
transcription start and end sites for each gene. We uti-
lized TagZilla (http://tagzilla.nci.nih.gov) to identify
haplotype tagging SNPs with an R2 criteria of 80%,
using a 10 kb upstream and downstream margin
around the start and end transcription site, to capture
important promoter and enhancer sites, resulting in a
of 1518 SNPs.
DNA genotyping and quality control
Single-nucleotide polymorphisms were genotyped by
the UNC Mammalian Genotyping Core using the
HumanCoreExome+ array from Illumina (Illumina,
Inc., San Diego, CA, USA). Samples and SNPs were
assessed for quality control using PLINK 1.07 (http://
pngu.mgh.harvard.edu/purcell/plink). SNPs were
excluded for missingness >5%, deviation from
Hardy–Weinberg Equilibrium (P < 1 9 103), and
minor allele frequency <5%. Samples were assessed
for call rate, sex discrepancies, relatedness, and
inbreeding. The full quality control process is
described in Supplementary Methods and Figures S1
and S2.




Preeclampsiaa • New onset systolic blood pressure ≥140 mm Hg or
diastolic blood pressure of ≥90 mmHg AND
• Proteinuria ≥0.3 g/24-h or ≥1+ on urine dipstick
1545
Preeclampsia subtypes
Severe preeclampsiaa General requirements of preeclampsia plus
• Systolic blood pressure of ≥160 mm Hg or diastolic
blood pressure of ≥110 mmHg OR
• Proteinuria ≥5 g/24-h or ≥3+ on urine dipstick
308
Early onset preeclampsia General requirements of preeclampsia plus
• Diagnosis prior to 34 completed weeks of gestation
277
Preeclampsia with early delivery General requirements of preeclampsia plus




General requirements of preeclampsia plus
• Infant born <10th percentile weight for gestational ageb
349
aCases with a validated diagnosis of eclampsia in the Medical Birth Registry of Norway were included in the preeclampsia and severe
preeclampsia phenotypes.
bPopulation percentiles derived from Norwegian distribution, eSnurra Norway.
The top three principal components of genetic vari-
ation were plotted for the MoBa data together with
the 1000 Genomes reference populations to assess evi-
dence of admixture (Figure S3). The final analysis
sample (n = 4551 total samples) included dyads with
both mother and child genotype data as well as
incomplete dyads with only mother or child genotype
data [n = 2621 preeclampsia case samples (1076
mother/child pairs, 459 mother only, 10 child only),
n = 1930 control samples (935 mother/child pairs, 46
mother only, 14 child only)].
Statistical analysis
To simultaneously account for maternal and child
genotype, we used the case-mother control-mother
log-linear modelling approach proposed by Shi
et al.21 This method uses Poisson regression to
model expected counts of each possible genetic
mating type combination under the assumption of
Mendelian inheritance. This method allows one to
account for the correlation between maternal and
child genotype and improves power compared to
a logistic model.21,22 Two maternal and two child
genetic risk parameters were included in the
model to saturate for codominant genetic main
effects, as follows:
ln E Nmcdð Þ½  ¼ hmc þ ddþ a1dIm¼1 þ a2dIm¼2
þ b1dIc¼1 þ b2dIc¼2
where E (Nmcd) is the expected value of the counts of
families with each of maternal genotypes, child geno-
types, and case or control status; d = 1 for a case and
d = 0 for a control; and I(m=j) and I(c=i) are indicators
for whether a mother or child has j (=one or two)
copies of the variant allele. The hmc parameters allow
flexibility of the control-mother distribution and
ensure that the parental genotype distribution is only
constrained by the family relationships.
To explore the potential for maternal–foetal interac-
tions, we expanded our model to include an indicator
for when the mother has more copies of the variant
allele than the child, described in the Supplementary
Methods.
LEM software23 was used to fit these models. The
expectation maximization algorithm was used to
incorporate dyads with missing genotypes. Likeli-
hood ratio tests comparing reduced models with the
saturated model were performed to determine
P-values for both maternal and child genetic effects,
each adjusted for the other genotype. A 4 degree-
of-freedom likelihood ratio test was used to determine
joint P-values for simultaneous tests of maternal/
child genetic effects. Point estimates and 95% confi-
dence intervals for relative risks were calculated for
each SNP for both maternal and child genotype.
To account for multiple comparisons, we calculated
the false discovery rate (FDR), which is the expected
proportion of type 1 errors (false positives) among all
positive tests.24 We used an FDR of <0.05 (reported as
Q-values) as our threshold for considering a finding
noteworthy.
Replication methods
All SNPs with Q-values ≤ 0.2 for both preeclamp-
sia overall and preeclampsia sub-phenotypes were
sent to the InterPregGen consortium for attempted
replication analysis.25 Within InterPregGen, cases
came from the UK Genetics of Pre-eclampsia
(GOPEC) consortium. The same standard definition
of preeclampsia defined cases. Population controls
came from the Wellcome Trust Case-Control Con-
sortium. Maternal samples (1875 cases, 5088 con-
trols) and child samples (1004 cases, 5286 controls)
were analysed separately for SNP associations with
preeclampsia using logistic regression, assuming a
logit-additive model. A subset included early
preeclampsia information, so were also analysed as
a proxy for the subtypes of preeclampsia with
additional complications (505 maternal cases, 5051
maternal controls, 276 child cases, 5297 child con-
trols). Complete methods for recruitment, genotyp-
ing, and quality control of the replication sample
are described in Supplementary Methods.
Results
The final analysis sample consisted of 4551 individual
samples for 2011 complete mother–child dyads, 505
samples with only maternal genotype data (459 cases),
and 24 children with only child genotype data (10
cases; n = 2540 pregnancies; Table 2). Mean maternal
age was 29.6 years (SD 4.7) and most had a university
degree. As expected, a greater proportion of women
with preeclamptic pregnancies were nulliparous and
of high body mass index (overweight or obese) com-
pared to those without preeclampsia. Babies born to
women with preeclampsia were more often preterm
confidence interval (CI) 1.19, 1.67 for 1 copy of the
minor allele and RR 2.12, 95% CI 1.46, 3.07 for 2 copies
(Q = 0.04) (Table 3). Although no maternal genotypic
associations met our FDR threshold, there were a
number of suggestive maternal genotypic associations
for SNPs in ESR1, PDE1C, PIK3C2G, and GUCY1A3.
Generally, the ESR1 and PDE1C SNPs were associated
with a reduced risk of preeclampsia and the PIK3C2G
and GUCY1A3 SNPs were associated with an
increased risk of preeclampsia, however, few showed
a dose–response pattern and risk ratios were mostly
null for the homozygous genotype. Table 3 shows
both mother and child effect estimates, and the joint
test results, for all top SNPs with FDR Q-values ≤0.20.
Excluding population outliers along axes of ancestral
variation did not substantially alter our findings
(See Figure S3, Table S2). All results for potential
maternal–foetal interactions were null (Table S4).
Because preeclampsia is a heterogeneous condi-
tion for which underlying aetiologies may differ,
we repeated the analysis within preeclampsia sub-
types. Results for subtype associations with Q ≤ 0.2
are presented in Table 4. Within subtypes, we
found associations for one SNP within PDE1C, a
maternal association of rs30593 (MAF = 0.35) for
preeclampsia accompanied by early delivery (RR
0.45, 95% CI 0.27, 0.75 for 1 copy; RR 1.44, 95% CI
0.63, 3.30 for 2 copies; Q = 0.02). A similar child
pattern was present for rs30562, another SNP in
PDE1C, but was just above our significance thresh-
old (Q = 0.06).
We provided the SNPs with Q ≤ 0.2 overall and
within subtypes to the InterPregGen Consortium
for analysis. Because we found different lead SNPs
among the general preeclampsia phenotype and
preeclampsia subtypes, in the replication sample we
assessed these SNPs for both associations with
overall preeclampsia (Table S3a) and early
preeclampsia (Table S3b), the only sub-phenotype
for which we had replication data. None of the
SNPs analysed were associated in the replication
dataset after correction for multiple testing. Our
lead SNP for preeclampsia with early delivery, a
maternal association of rs30593 in PDE1C, was
nominally associated (uncorrected P = 0.05) in the
replication cohort, but in the child population. As
with this SNP in the MoBa study, we saw a similar
reduced risk of preeclampsia (RR 0.90, 95% CI 0.82,
1.00) in the replication study. Complete replication
results are reported in Table S3.
Table 2. Demographic characteristics of pregnancies in the final






No. % No. %
Maternal age [mean(SD),
years]
29.3 (4.9) 30.1 (4.4)
Maternal education
<High school 132 8.5 73 7.3
High school graduate 439 28.4 264 26.5
University degree 831 53.8 574 57.7
Missing 143 9.3 84 8.4
Body mass index (kg/m2)
Underweight (<18.5) 25 1.6 32 3.2
Normal weight (18.5–24.9) 712 46.1 629 63.2
Overweight (25.0–29.9) 444 28.7 186 18.7
Obese (30.0+) 264 17.1 95 9.6
Missing 100 6.5 53 5.3
Maternal smoking
Smoking in weeks 11–20 120 7.8 95 9.6
Missing 83 5.4 44 4.4
Smoking in third trimester 71 4.6 64 6.4
Missing 159 10.3 86 8.6
Nulliparous 1012 65.5 407 40.9
Preterm (< 37 weeks) 332 21.5 33 3.3
Small for gestational age (SGA)
(<10th percentile)a
349 22.6 77 7.7
Preeclampsia subtypes
Severe 308 19.9
Onset <34 weeks 277 17.9
Delivery <34 weeks 132 8.5
Accompanied by SGAa 349 22.6
aPopulation percentiles derived from Norwegian distribution,
eSnurra Norway.
and small-for-gestational-age (SGA). Severe preeclamp-
sia (including eclampsia) was present in 20% of women 
with preeclampsia.
Results of tests for maternal genotypic associations 
controlling for child genotype are summarized in Fig-
ure S3a and for child genotypic associations control-
ling for maternal genotype are summarized in 
Figure S3b. In the joint 4-degree of freedom test, we 
found one SNP to be significant (Q ≤ 0.05), however, 
this SNP was only individually significant in the child 
and not in the mother. We found a child association of 
increasing risk in the variant allele of this SNP 
(rs12547243, MAF = 0.29), a synonymous substitution 
in a coding region of ADCY8 on chromosome 8. The 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this large, family based case–control study of
genetic variants in CO and NO pathways and
preeclampsia, there were no replicated associations
between CO and NO variants and risk of preeclamp-
sia. However, this study demonstrates the utility of
using a dyad approach and provides information
about potential genetic associations of interest within
both the mother and the child. In the child, rs12547243
in ADCY8, a SNP with no previously reported associa-
tions, was associated with preeclampsia in Norwegian
women. The AG and AA genotypes were associated
with increased risk of preeclampsia as compared with
the GG genotype. There were no maternal genotypic
associations with preeclampsia overall that met the
FDR threshold (Q < 0.05). Among preeclampsia sub-
types, there was a decreased risk of preeclampsia
accompanied by early delivery associated with the
TC maternal genotype as compared to CC genotype
of rs30593 in PDE1C. However, none of these associ-
ations were replicated in the InterPregGen study. Of
all the lead SNPs that were sent for replication test-
ing, only rs30593 in PDE1C was nominally associ-
ated with preeclampsia in the replication sample
(P = 0.05), however, this association was found in
the child (rather than the mother as in the MoBa
cohort) and was not significant after adjustment for
multiple testing.
Interpretation
The potential role of nitric oxide and carbon monox-
ide in the development of preeclampsia is an ongoing
area of research. In this study, none of the SNPs in the
most widely studied candidate genes for preeclamp-
sia in the CO and NO pathways, NOS2 or NOS3, were
associated with preeclampsia, however, prior associa-
tions were found in small and ethnically diverse pop-
ulations.8,15 Although not replicated, there were some
interesting associations that have been supported by
animal studies of preeclampsia26 or are more broadly
associated with cardiovascular outcomes in GWA
studies27–29 and warrant further investigation. Clinical
trials are currently underway for the treatment of
preeclampsia with pharmaceuticals whose mecha-
nism is via nitric oxide signalling, including hydrox-
ymethylglutaryl-CoA reductase inhibitors (‘statins’)
and phosphodiesterase inhibitors.30 Several SNPs of
interest in our analysis (Q < 0.1) are located in the
genes ADCY8, GUCY1A2, GUCY1A3, and PDE1C,
which are all part of the canonical pathway for cellu-
lar effects of sildenafil (‘Viagra’), a phosphodiesterase
inhibitor that operates through nitric oxide signalling
to increase vasodilation.31 Mouse studies have
demonstrated resolution of the preeclampsia pheno-
type with the administration of sildenafil26 and it is
now being investigated for treatment of preeclampsia
and foetal growth restriction.30
Although there were a few associations of interest
in the MoBa sample, these were not replicated in the
InterPregGen analysis. It is plausible that some of the
associations failed to replicate due to different ana-
lytic methods and a somewhat different outcome
assessment in the primary analysis and replication
datasets. While both populations used the same defi-
nition of preeclampsia, the MoBa analysis used only
validated cases and non-cases, whereas the InterPreg-
Gen Consortium used validated cases but population
controls that may or may not be pregnant women.
Overall allele frequencies for SNPs in the replication
analysis were similar between the MoBa sample and
the InterPregGen sample, but differed by case–control
status in both mothers and children for SNPs associ-
ated with preeclampsia in the MoBa sample
(Table S5). In addition, in the MoBa analysis, both
mother and child genotypes were included and mod-
elled codominantly with a genetic mating type param-
eter to account for mother-child family structure; by
contrast, the replication analysis independently mod-
elled mother and child genotype logit-additively. To
investigate how a similar type of analysis might alter
these results, maternal and child samples from the
MoBa sample were analysed using standard logistic
regression analysis modelled additively in PLINK.
Associations with rs12547243 in the child were stron-
ger, but other associations were attenuated (data not
shown).
The largely null findings of this study demonstrate
the challenges of the genetic study of preeclampsia.
Despite a clear a priori hypothesis, large sample size,
well-validated outcome, and population with little
admixture used to study a condition for which there
is strong evidence of heritability, associations were
not replicated in another population. Although both
maternal and foetal genes should be considered
because they may differentially affect preeclampsia
independently or through their interaction, the
from population stratification bias because the families
essentially serve as their own controls, but use of dyads
in which mating-type frequencies may differ between
cases and controls retains possible confounding by
ancestry; thus, the case-mother control-mother design
is not as robust to population stratification as a trio
design would be. To address this limitation, popula-
tion stratification was assessed in the quality control
process to determine if ancestral homogeneity was a
plausible assumption within this Norwegian cohort.
Survey information about ethnicity is limited to first-
language spoken by parents and grandparents. Com-
paring the MoBa population with the 1000 Genomes
reference populations, a handful of MoBa participants
were identified who clustered with Chinese, Amerin-
dian, and Nigerian ancestral populations (Figure S3).
Excluding such observations in a sensitivity analysis,
however, did not change results, indicating that popu-
lation stratification bias is not a serious issue (Supple-
mentary Methods). However, the results of this study
aremost generalizable to populations of European des-
cent. This study may be affected by selection bias if
similar genetic factors that influence preeclampsia also
influence study participation. When MoBa study par-
ticipants were compared with the population of all
births in Norway during the same period, prevalence
of preeclampsia was similar, but women inMoBa were
less likely to be young, live alone, smoke, and have
more than two births.35 When associations between
covariates and birth outcomes in the two populations
were compared, however, there were few differences
(e.g. the ratio of adjusted odds between smoking and
low birthweight and between parity and preeclampsia
were approximately 1.0).35 To address the possibility
that prior birth outcome may affect participation in the
study, a sensitivity analysis was conducted restricting
the analysis to primiparous women and results were
unchanged (data not shown). In addition, despite
being the largest study, power is still limited. A dyad
design improves statistical power, but is slightly less
powerful than other family based designs, such as
trios. Although there were some interesting trends and
suggested associations, larger studies are needed to
study these associations in greater detail.
Conclusions
In conclusion, this study uses a novel design to
disentangle maternal and child genotypic effects of
NO and CO signalling genes on preeclampsia. The
aetiology of preeclampsia likely includes both poly-
genecity as well as phenotypic heterogeneity, under-
scoring the need for very large sample sizes.
Strengths of the study
This study is one of the largest genetic studies of 
preeclampsia to date, with 1076 case pairs (2152 sam-
ples) and 935 control pairs (1870 samples), with access 
to both maternal and child DNA. Given the suspected 
pathophysiology underlying preeclampsia, it is bio-
logically plausible that both maternal and child geno-
types contribute to this pregnancy complication. This 
dyad analysis accounted for family structure, and has 
been implemented for other child phenotypes in 
which both maternal and child genotype may play a 
role,32 but has not been explored for pregnancy com-
plications. Although a few other studies of 
preeclampsia have examined child genotype,33,34 to 
our knowledge, none have simultaneously modelled 
both mother and child. Mother and child genotype 
may independently contribute to the development of 
preeclampsia,13 but it is also possible that maternal 
and child genetic factors may act synergistically or 
antagonistically through their interaction. The dyad 
design allowed for preliminary investigation of 
maternal–foetal interactions.
Candidate gene studies have inconsistently repli-
cated, possibly in part due to the fact that few studies 
adequately considered variability across the gene. 
This study aimed to improve upon prior candidate 
gene studies by providing a more comprehensive cov-
erage of genetic variation across the genes, while con-
tinuing to apply a hypothesis-driven approach to 
conserve statistical power.
A significant strength of our study was the verifica-
tion of the clinical endpoint by antenatal medical 
records and hospital diagnostic codes through medi-
cal record validation.19 This also enabled classification 
of cases into subtypes that may have differing under-
lying aetiologies.
Limitations of the data
Although the analytic method allowed control for 
paired genotypes, which is likely the biggest con-
founder, a limitation of this study design is the inability 
to control for external confounders, such as using prin-
cipal components to adjust for population admixture. 
Family based case-parent trio designs are protected
results of this study highlight the challenges of
discovering replicated SNPs across multiple popu-
lations, even for highly heritable perinatal condi-
tions, like preeclampsia, and demonstrate the
unique challenges of conditions that may be influ-
enced by both mother and child. Future research
of genetics and preeclampsia should continue to
incorporate maternal and child genetic components
and expand to explore maternal–child genotypic
interactions as well as interactions with exogenous
sources of CO and NO.
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Figure S1. Quality control and sample selection pro-
cess.
Figure S2. Quality control quantile–quantile plots for
maternal and child genotypic effects among genome-
wide data of 263 494 variants to assess genomic infla-
tion. Test results (observed -log10p values) are plotted
against the expected -log10p values for each of 263 494
SNPs in the sample.
(a) Q-Q plot of maternal genotypic effects among
maternal samples. Genomic inflation factor,
lambda = 1.01. (b) Q-Q plot of child genotypic effects
among child samples. Genomic inflation factor,
lambda = 1.03.
Figure S3. Top three axes of genetic variation based
on common SNPs for our Norwegian Mother and
Child Cohort sample (MOBA) compared to 1000 Gen-
omes reference populations. Plots are show for axes 1
and 2, axes 1 and 3, and axes 2 and 3. Reference popu-
lations are: CEU: Utah Residents with Northern and
Western Ancestry; CHB: Han Chinese in Beijing,
China; PUR: Puerto Ricans from Puerto Rico; MXL:
Mexican Ancestry from Los Angeles, USA; CLM:
Colombians from Medellin, Colombia; YRI: Yoruban
in Ibadan, Nigeria.
Figure S4. Quantile–quantile plots for maternal and
child genotypic effects. Test results (observed -log10p
values) are plotted against the expected -log10p values
for each of 1518 SNPs across 66 loci in the sample.
Figure S4. (a) Q-Q plot of maternal genotypic effects,
adjusting for child genotype. Genomic inflation factor,
lambda = 1.18. (b) Q-Q plot of child genotypic effects,
adjusting for maternal genotype. Genomic inflation
factor, lambda = 1.09.
Figure S5. Case and control status of the study sample
plotted along the first two axes of variation for genetic
ancestry.
Table S1. List of genes and canonical pathways.
Table S2. (a) Sensitivity analysis results. Summary of
SNPs with FDR Q ≤ 0.2 in the full cohort analysis
excluding samples with first principal component
>0.04 (n = 1994 mother-child dyads). (b) Sensitivity
analysis results. Summary of SNPs FDR Q ≤ 0.2 in the
full cohort analysis excluding samples with first prin-
cipal component >0.01 (n = 1964 mother-child dyads).
Table S3. (a) Replication results for preeclampsia
overall in the UK GWAS cohort for SNPs with FDR
Q ≤ 0.2 in the MoBa analysis. (b) Replication results
for early preeclampsia in the UK GWAS cohort for
SNPs with FDR Q ≤ 0.2 in the MoBa analysis.
Table S4. Summary of SNPs with P < 0.01 for tests for
maternal–child genotype interactions for preeclamp-
sia overall, indicated by number of maternal copies of
the variant allele being greater than number of child
copies of the variant allele.
Table S5. Minor allele frequencies for cases and con-
trols in the MoBa sample and InterPregGen replica-
tion sample for all SNPs included in the replication
analysis (SNPs with FDR Q ≤ 0.2).
Table S6. Reference alleles for mothers and children.
